Hepatitis B is potentially a life-threatening liver infection caused by the Hepatitis B Virus (HBV). It is a major global health problem and it can be an acute infection or a chronic infection. Chronic HBV infection is a leading cause of chronic hepatitis and advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
DelveInsight’s “Hepatitis B Virus (HBV) Infection Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hepatitis B Virus (HBV) Infection, historical and forecasted epidemiology as well as the Hepatitis B Virus (HBV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hepatitis B Virus (HBV) Infection Market key facts
-
In the Global Burden of Disease Study, 2010, HBV Infection is estimated to have 786,000 deaths and the vast majority being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths), as per Lozano et al., 2012.
-
According to the World Health Organization, about 2 billion people worldwide have been infected with the Hepatitis B Virus and about 360 million live with chronic Hepatitis B infection.
-
As per European Centre for Disease Prevention and Control (ECDC), the prevalence of HBV in the general population is heterogeneous in Europe ranging 0.1-7 % depending on the country.
Hepatitis B Virus (HBV) Infection Market Analysis
-
The Hepatitis B Virus (HBV) Infection market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hepatitis B Virus (HBV) Infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
-
The report gives a thorough detail of Hepatitis B Virus (HBV) Infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hepatitis B Virus (HBV) Infection Epidemiology
-
The Hepatitis B Virus (HBV) Infection epidemiology section covers insights about historical and current Hepatitis B Virus (HBV) Infection patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
-
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hepatitis B Virus (HBV) Infection Drugs Uptake and Key Market Players
-
The Hepatitis B Virus (HBV) Infection Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B Virus (HBV) Infection market or expected to get launched in the market during the study period. The analysis covers Hepatitis B Virus (HBV) Infection market uptake by drugs; patient uptake by therapies; and sales of each drug.
-
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the key players, such as Ascentage Pharma, Replicor, Ionis Pharma, Gilead Sciences, Arbutus Biopharma, Spring Bank Pharmaceuticals, MYR Pharma, GC Pharma, and Altimmune, etc. are involved in developing therapies for Hepatitis B Virus (HBV) Infection infection.
For more details on Hepatitis B Virus Infection Market Analysis, visit:
https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-market